These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34648119)

  • 41. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
    Schoenbeck KL; Atallah E; Lin L; Weinfurt KP; Cortes J; Deininger MWN; Kota V; Larson RA; Mauro MJ; Oehler VG; Pinilla-Ibarz J; Radich JP; Schiffer CA; Shah NP; Silver RT; Thompson JE; Flynn KE
    J Natl Cancer Inst; 2022 Jan; 114(1):160-164. PubMed ID: 34491344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
    Jiang Q; Liu ZC; Zhang SX; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Cure of Chronic Myeloid Leukemia: Are We There Yet?
    Saikia T
    Curr Oncol Rep; 2018 Feb; 20(2):12. PubMed ID: 29492683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
    Efficace F; Baccarani M; Breccia M; Alimena G; Rosti G; Cottone F; Deliliers GL; Baratè C; Rossi AR; Fioritoni G; Luciano L; Turri D; Martino B; Di Raimondo F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Ulisciani S; Veneri D; Sica S; Rambaldi A; Vignetti M; Mandelli F;
    Blood; 2011 Oct; 118(17):4554-60. PubMed ID: 21750313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience.
    Ureshino H; Kamachi K; Nishioka A; Okamoto S; Katsuya H; Yoshimura M; Kubota Y; Ando T; Kimura S
    Hematol Oncol; 2021 Oct; 39(4):549-557. PubMed ID: 34117654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Chronic myeloid leukemia: aiming for treatment free remission].
    Kimura S
    Rinsho Ketsueki; 2021; 62(6):572-581. PubMed ID: 34219083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
    Baccarani M; Abruzzese E; Accurso V; Albano F; Annunziata M; Barulli S; Beltrami G; Bergamaschi M; Binotto G; Bocchia M; Caocci G; Capodanno I; Cavazzini F; Cedrone M; Cerrano M; Crugnola M; D'Adda M; Elena C; Fava C; Fazi P; Fozza C; Galimberti S; Giai V; Gozzini A; Gugliotta G; Iurlo A; La Barba G; Levato L; Lucchesi A; Luciano L; Lunghi F; Lunghi M; Malagola M; Marasca R; Martino B; Melpignano A; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Pregno P; Rapezzi D; Rege-Cambrin G; Rupoli S; Salvucci M; Sancetta R; Sica S; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Trabacchi E; Bonifacio M; Breccia M; Castagnetti F; Pane F; Russo D; Saglio G; Soverini S; Vigneri P; Rosti G
    Blood Adv; 2019 Dec; 3(24):4280-4290. PubMed ID: 31869412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy.
    Oswald LB; Hyland KA; Eisel SL; Hoogland AI; Knoop H; Nelson AM; Pinilla-Ibarz J; Sweet K; Jacobsen PB; Jim HSL
    Support Care Cancer; 2022 Jan; 30(1):87-94. PubMed ID: 34231041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
    Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
    Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive Behavioral Therapy for Treatment-Related Fatigue in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitors: A Mixed-Method Study.
    Poort H; Onghena P; Abrahams HJG; Jim HSL; Jacobsen PB; Blijlevens NMA; Knoop H
    J Clin Psychol Med Settings; 2019 Dec; 26(4):440-448. PubMed ID: 30747340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.
    Kennedy JA; Hobbs G
    Curr Hematol Malig Rep; 2018 Jun; 13(3):202-211. PubMed ID: 29687320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health-related quality of life in children with chronic myeloid leukemia in the chronic phase.
    Zheng F; Dou X; Zhang L; Jin J; Zhang Y; Liu B; Meng L; Zhu X; Lu Z; Jia Y; Liu H; Lin H; Zhou L; Zhao X; Yang W; Sun H; Qian S; Ma H; Wu R; Zhang L; Jiang Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):341-350. PubMed ID: 34714411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia].
    Slezáková K; Mistrík M; Bátorová A
    Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Lee H; Basso IN; Kim DDH
    Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.